Exclusive-Cigna settles FTC insulin case, commits to overhauling drug pricing

Core Insights - Cigna Corp's Express Scripts has settled claims from the U.S. Federal Trade Commission regarding antitrust violations in insulin pricing practices, agreeing to changes that aim to reduce costs for patients, insurers, and small pharmacies [1][2] Group 1: Settlement Details - The settlement aligns with the Trump administration's efforts to lower drug costs and allows the FTC to reduce a case initiated by the Biden administration against Express Scripts, UnitedHealth Group's Optum, and CVS Health's Caremark, with ongoing cases against Optum and Caremark [2] - The 10-year agreement restricts Express Scripts from engaging in practices that contribute to high costs, such as retaining rebate payments from drugmakers based on list prices, potentially saving patients up to $7 billion over the decade [4] - Express Scripts is now legally bound to comply with the settlement terms and will be monitored for three years [4] Group 2: Industry Context - Pharmacy benefit managers have faced scrutiny for pricing practices, with the FTC accusing them of directing patients and insurers towards higher-priced drugs to maximize profits [5] - The settlement requires Express Scripts to collaborate with local pharmacies and disclose drug costs to employers annually [5] - Cigna's insurance business primarily manages plans for employers, and the settlement mandates that direct-to-consumer drug purchases through the planned TrumpRX platform count towards copays and deductibles in standard employer plans [6] Group 3: Industry Trends - In recent years, CVS, UnitedHealth, and Cigna have introduced new pricing models aimed at increasing transparency regarding discounts, fees, and drug costs, shifting revenue models towards administrative fees rather than hidden reimbursements from drugmakers [7]